Anti-TNF, thiopurine combination increase lymphoma risk in IBD

Patients with inflammatory bowel disease treated with anti-TNF either as a monotherapy or in combination with thiopurines are at increased risk for lymphoma, according to study results.Franck Carbonnel, MD, of the department of gastroenterology at Hôpital de Bicêtre, Assistance Publique-Hôpitaux de Paris, and colleagues wrote that despite their efficacy in patients with IBD, anti-TNF agents come with risks, as do thiopurines.“These medications have potential serious adverse effects such as infections and malignancy,” they wrote. “Lymphoma has been shown toRead More

Share on facebook
Share on twitter
Share on linkedin